Diagonal Bio
0.012
SEK
-9.77 %
Less than 1K followers
DIABIO
First North Stockholm
Biotechnology & Pharmaceuticals
Health Care
Overview
Financials & Estimates
Ownership
-9.77%
-24.05%
+11.21%
-7.23%
-7.69%
-72.31%
-98.74%
-
-99.66%
Diagonal Bio operates in the biotechnology industry. The company is developing a platform under the name Panviral to detect and diagnose small sections of pathogen genomes, such as viruses, bacteria, and fungi. In addition to the main business, service and associated ancillary services are also offered. The largest operations take place in Sweden with headquarter in Lund.
Read moreMarket cap
14.58M SEK
Turnover
63.74K SEK
Revenue
20K
EBIT %
-57,850 %
P/E
-
Dividend yield-%
-
Financial calendar
28.3
2025
Annual report '24
14.5
2025
Interim report Q1'25
20.5
2025
General meeting '25
ShowingAll content types
Diagonal Bio AB: Diagonal Bio has received conditional approval for listing on NGM Nordic SME
Diagonal Bio AB: Diagonal Bio applies for change of marketplace to NGM Nordic SME
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools